Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Medical Oncology

• Publication date

  2016-06-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12032-016-0788-yPMID 27282497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach

  2016cited by this paper
• Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer

  2015cited by this paper
• Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.

  2015cited by this paper
• Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer

  2015cited by this paper
• Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response

  2015cited by this paper
• Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

  2015influential reference
• Delay in presentation to the hospital and factors affecting it in breast cancer patients attending tertiary care center in Central India.

  2015cited by this paper
• Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women

  2015cited by this paper
• Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study

  2015cited by this paper
• Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

  2015cited by this paper
• Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

  2014cited by this paper
• Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway.

  2014cited by this paper
• Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.

  2014cited by this paper
• PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.

  2014cited by this paper
• PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

  2014cited by this paper
• Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.

  2013cited by this paper
• Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.

  2013influential reference
• PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

  2012cited by this paper
• Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)

  2012cited by this paper
• PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

  2012influential reference
• KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer

  2012cited by this paper
• PIK3CA mutations in in situ and invasive breast carcinomas.

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

  2010cited by this paper
• Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type

  2010cited by this paper
• Targeting PI3K signalling in cancer: opportunities, challenges and limitations

  2009cited by this paper
• PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

  2009influential reference
• Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

  2009cited by this paper
• Class I PI3K in oncogenic cellular transformation

  2008cited by this paper
• PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

  2008cited by this paper
• PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

  2008cited by this paper
• PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

  2008cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008cited by this paper
• Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas

  2007cited by this paper
• PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

  2007cited by this paper
• Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women

  2007influential reference
• PIK3CA mutations in breast cancer are associated with poor outcome

  2006cited by this paper
• Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

  2005cited by this paper
• Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers

  2005cited by this paper
• PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas

  2005cited by this paper
• MicroRNAs as potential diagnostic markers of disease

  2005cited by this paper
• PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  2005cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• PI3K-Akt pathway: Its functions and alterations in human cancer

  2004cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Chinese a Nti鄄 Cancer a Ssociation

  year unknowncited by this paper
• Open Access Research

  year unknowncited by this paper

• "Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer.

  2026cites this paper
• Prevalence and spectrum of PIK3 mutations in breast cancer and their correlation with clinicopathological features: A cross-sectional observational study from South India

  2025cites this paper
• mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation

  2024cites this paper
• Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

  2023cites this paper
• Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations

  2022cites this paper
• BRCA1, BRCA2, TP53, PIK3CA, PTEN and AKT1 genes mutations in Burkina Faso breast cancer patients: prevalence, spectrum and novel variant

  2022cites this paper
• PIK3CA, KI67, Estrogen and Progesterone Receptors Expression Pattern in HER2 Positive Breast Cancers

  2022cites this paper
• Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China.

  2022cites this paper
• The evaluation of PIK3CA gene variation and serum PI3K level in breast cancer risk and prognosis in Turkish population

  2021cites this paper
• PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing

  2021cites this paper
• Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA)

  2020cites this paper
• A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

  2020cites this paper
• Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

  2019cites this paper
• Plasma PIK 3 CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer

  2018cites this paper
• Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.

  2018cites this paper
• Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients

  2018cites this paper
• Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

  2018influential citation
• Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients

  2018cites this paper
• Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

  2017cites this paper
• Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis

  2017cites this paper
• PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients

  2017influential citation